REGN7075 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for REGN7075 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Colonic Neoplasms. Most recent publication: EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease., Future Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.
    Saeed A, Yothers G, Puhalla SL, et al. · Future Oncol · 2026
    PubMed: PMID 42345857 · NCT07058012 (EMPIRE) · Colonic Neoplasms

Publications by year

2026–2026: 1 publications.

2026
1

Publications by indication

Colonic Neoplasms (1)

  • EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.
    Future Oncol · 2026 · PMID 42345857 · NCT07058012

Publications by journal

  • Future Oncol1 paper

All REGN7075 publications (1)

2026 (1 paper)

  1. EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.
    Saeed A, Yothers G, Puhalla SL, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 42345857 · NCT07058012 (EMPIRE) · Colonic Neoplasms

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Fri, 17 Jul 2026 04:05:29 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).